INTRODUCTION
Gliclazide 1-(Hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3- [(4-methylphenyl) sulphonyl]urea (Figure 1 ), is an oral hypoglycemic drug, belonging to secondgeneration sulphonylureas, used in type-II diabetes (Gunawan et al., 2007) . Different analytical methods including HPLC (British Pharmacopoeia Commission, 2009 ) and spectrophotometric UV-VIS (Revathi et al., 2010; Samina et al., 2011) estimation of gliclazide in dosage forms have been reported for determination of gliclazide. However, no TLC densitometry method is available for quantitative determination of gliclazide in its pharmaceutical dosage forms. Some reported analytical methods are both time and money consuming (Wulandari et al., 2012) . There is a need for a simple, rapid, cost effective and reproducible method for assay of gliclazide in its dosage forms. Therefore, it was thought of interest to develop simple, rapid, accurate, specific and precise TLC method for the analysis of gliclazide in its tablet formulation. The objective of the current work is, therefore, to develop a simple TLC method for analysis of gliclazide in tablet formulations.
EXPERIMENTAL

Materials and Reagents
Gliclazide working standard was a generous gift (Shandong Keyuan Pharmaceutical, Co., LTD; Batch No. 1003-221; Assay 99.2, Expired date: 24 Maret 2014) from Ikapharmindo, Jakarta, Indonesia. Toluen, chloroform (Merck) and ethyl acetate (Riedel-de Haën) were of pharmaceutical grade reagents. Commercial tablet containing 80 mg gliclazide were purchased from local pharmacy in Jember, East Java, Indonesia (April 2012).
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Standard Preparation
Stock standard solution was always freshly prepared by dissolving gliclazide (10 mg) in 25 ml chloroform (400µg/ml).
Sample Preparation
Two brands of tablets A and B were selected. Twenty tablets were weighed and the average weight was calculated. The tablets were then powdered and an amount equivalent to 10 mg of gliclazide was dissolved in 25ml volumetric flask, and approximately 15ml of chloroform was added. The mixture was ultrasonicated for 15 min and diluted to 25ml with the same solvent. This solution was filtered through a Nillon paper.
TLC Method and Chromatographic Condition
Chromatographic was performed on precoated 20cm x 10cm TLC silica gel GF 254 alumuniumbacked sheets Merck. A Blaubrand equipped with 2.0 µl glass capillaries. A Camag Twin Trough Chamber was saturated for 30 min with the mobile phase containing a mixture of toluene: ethyl acetate in the ratio of 1:1 (v/v). After chamber saturation, the plates were developed to a distance of 9 cm. Densitometric analysis was carried out using a Camag TLC Scanner 3 (Camag) in the absorbance mode at 234 nm for all measurements. The slit dimension was kept at 6.00 mm × 0.30 mm and a scanning speed of 20 mm/s was employed. Gliclazide was detected at Rf of 0.58. The chromatograms were integrated using winCATS evaluation software (Version 1.4.1.8154).
Method validation
Validation of the optimized TLC method was carried out with respect to the following parameters.
Specificity
The specificity of the method was ascertained by analyzing standard drug and sample. Specificity is showed by purity and identity test. The purity and identity of the analyte spots were determined by scanning 200 nm-400 nm. Calculations for identity checks (rS.S and rS,A where S is spectrum standard and A is spectrum sample and purity checks (rS,M and rM,E where S = start, M = center; and E = end of spectrum)
Linearity
Standard solution were prepared containing 150, 200, 300, 400, 450, 600, 750, 800µg/ml and 2µl of each of these solutions was spotted on the TLC plate. Peak area was recorded for each concentration and a calibration plot was obtained by plotting peak area against concentration.
Limit of Detection and Quantification
Standard solution were prepared containing 50, 75, 
Accuracy
Recovery studies were carried out to check the accuracy of the method. Recovery experiments were performed by adding three different amounts of pure gliclazide i.e., 30, 45 and 60% of the labeled amount of gliclazide analyzed from the gliclazide formulations and the resultant were reanalyzed (n = 3).
Analysis of marketed formulation
Twenty tablets of each brands were weighed their average weight calculated, tablets finely powdered and the powder equivalent to containing 10 mg of Gliclazide from sample brand A and brand B 25 ml of chloroform. The solution was sonicated for 15 min and then filtered through Nilln paper. Each of these solutions (2 μl) were spotted on plates and analyzed for gliclazide in the same way as described earlier. Table 1 showed optimum conditions for analysis gliclazide using TLC. The mobile phase of toluene:ethyl acetate (1,0 : 1.0, v/v) gave efficiency chromatogram (N value is bigger and H is smallest) with Rf value 0.58 for glicazide and a sharp and symmetrical peak. The analytical wavelength, 234 nm, was chosen on the basis of the absorption spectrum recorded in the range 200-400 nm. Concentration optimum 400 ppm (µg/ml) was chosen on the basis of efficiency chromatogram and % recovery 90%-107% (Huber, 2007) [ Figure 1 ].
RESULTS AND DISCUSSION
Optimum condition
Validation of the method
The proposed TLC system demonstrated that all analyte spots in samples furnished in situ uv spectra that were identical to those of standards (rS.S and rS,A ≥ 0.99). Purity check of the analyte spots using the winCATS software also showed that analyte spots of the extract were pure. The values of rS,M and rM,E were ≥0.99, demonstrating that the proposed TLC method is highly specific. Linearity of gliclazide was achieved from 300-1600 ng/spot (n= 8) obeying the equation Y= 513.956+4.525x with r 0,999. The liniear regression data is presented in Figure 3 . The LOD and LOQ (Limit of Detection and Quantification) were found to be 28.78 and 86.35 ng/spot respectively.
All the values of the repeatability and intermediate precision evaluation were less than 5.3% (Table 2) . These values were also less than the required values (5.3%; specification range of 90%-107%; n=6) (Huber, 2007) The three measurement were perfomed within one laboratory by same analyst on different plates and different days. 
RESULTS AND DISCUSSION
method) againts Xc (nominal precentage of label claim of the analyte after addition with the standards). The data of summary of validation parameters are listed in Table 5 .
Analysis of marketed formulations
A single spot at Rf 0.58 was observed in the densitogram of the drug samples extracted from tablets. There was no interference from the excipients commonly present in the tablets. The results, given in Table 4 , indicate that the amount of drug in the tablets is within the requirement of 95%-105% of the label claim. The percentage recovery values for brand A and brand B were found to be 100.494%±0.348 and 100.111%±1.257% respectively .
CONCLUSION
A new TLC method has been developed for the identification and quantification of gliclazide in formulations. The method was found to be simple, rapid, specific, sensitive, precise and accurate for estimation and can be conveniently employed for the routine quality control analysis of gliclazide from tablets. 
